
Clive A Holmes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8138411/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
2	A case-control study of the locus coeruleus degeneration in Alzheimer's disease. European Neuropsychopharmacology, 2021, 43, 153-159.	0.7	20
3	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
4	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. Journal of Alzheimer's Disease, 2021, 83, 5-22.	2.6	52
5	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. Translational Psychiatry, 2020, 10, 267.	4.8	30
6	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1219-1226.	1.9	17
7	Psychological stress, cognitive decline and the development of dementia in amnestic mild cognitive impairment. Scientific Reports, 2020, 10, 3618.	3.3	21
8	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. PLoS ONE, 2019, 14, e0218111.	2.5	23
9	Microglial motility in Alzheimer's disease and after Aβ42 immunotherapy: a human post-mortem study. Acta Neuropathologica Communications, 2019, 7, 174.	5.2	35
10	Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. Translational Psychiatry, 2019, 9, 154.	4.8	69
11	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
12	Downregulated apoptosis and autophagy after antiâ€Aβ immunotherapy in Alzheimer's disease. Brain Pathology, 2018, 28, 603-610.	4.1	24
13	Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 88.	5.2	52
14	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. Brain, Behavior, and Immunity, 2017, 62, 212-218.	4.1	132
15	Costâ€effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the) Tj ETQq1 1 0).784314 rg 2.7	gBT_{Qverlock
16	EMERGING CONCEPTS IN BASIC SCIENCE: PANEL SESSION. Alzheimer's and Dementia, 2017, 13, P1224.	0.8	0
17	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. PLoS ONE, 2017, 12, e0179521.	2.5	48
18	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 85.	6.2	52

CLIVE A HOLMES

#	Article	IF	CITATIONS
19	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment, 2017, 21, 1-192.	2.8	37
20	Targeting innate immunity for neurodegenerative disorders of the central nervous system. Journal of Neurochemistry, 2016, 138, 653-693.	3.9	106
21	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. Trials, 2016, 17, 324.	1.6	6
22	Periodontitis and Cognitive Decline in Alzheimer's Disease. PLoS ONE, 2016, 11, e0151081.	2.5	289
23	Etanercept in Alzheimer disease. Neurology, 2015, 84, 2161-2168.	1.1	203
24	Effect of amyloidâ€Î² (<scp>A</scp> β) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase <scp>(GSK</scp>)â€3β. Neuropathology and Applied Neurobiology, 2015, 41, 445-457.	3.2	17
25	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	10.2	4,129
26	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurology, The, 2015, 14, 1171-1181.	10.2	124
27	Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain, 2015, 138, 3673-3684.	7.6	359
28	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
29	Microglial priming in neurodegenerative disease. Nature Reviews Neurology, 2014, 10, 217-224.	10.1	827
30	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
31	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
32	Intravenous immunoglobulin for Alzheimer's disease. Lancet Neurology, The, 2013, 12, 218-219.	10.2	6
33	Systemic inflammation and Alzheimer's disease. Biochemical Society Transactions, 2011, 39, 898-901.	3.4	67
34	Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry, 2011, 26, 812-817.	2.7	126
35	Role of Infection in the Pathogenesis of Alzheimer's Disease. CNS Drugs, 2009, 23, 993-1002.	5.9	66
36	Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, The, 2008, 372, 216-223.	13.7	1,333

CLIVE A HOLMES

#	Article	IF	CITATIONS
37	Keep music live: music and the alleviation of apathy in dementia subjects. International Psychogeriatrics, 2006, 18, 623-630.	1.0	133
38	Reply to "Specificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease― Nature Medicine, 2004, 10, 118-119.	30.7	12
39	Depression in Alzheimer's disease: The effect of serotonin receptor gene variation. American Journal of Medical Genetics Part A, 2003, 119B, 40-43.	2.4	58
40	Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age and Ageing, 2003, 32, 200-204.	1.6	71
41	Genotype and phenotype in Alzheimer's disease. British Journal of Psychiatry, 2002, 180, 131-134.	2.8	91
42	The clinical phenotype of familial and sporadic late onset Alzheimer's disease. International Journal of Geriatric Psychiatry, 2002, 17, 146-149.	2.7	14
43	Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. International Journal of Geriatric Psychiatry, 2002, 17, 305-308.	2.7	159
44	Contribution of Genetics to the Understanding of Behavioral and Psychological Symptoms of Dementia. International Psychogeriatrics, 2000, 12, 83-88.	1.0	5
45	Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. British Journal of Psychiatry, 1999, 174, 45-50.	2.8	329